Carvedilol: Molecular and cellular basis for its multifaceted therapeutic potential

Cardiovascular Drug Reviews

Volumn 19, Issue 2, 2001, Pages 152-171

  Cheng, Jianhua ^b   Kamiya, Kaichiro ^a   Kodama, Itsuo ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b TONGJI UNIVERSITY   (China)

Author keywords

Adrenoceptor blockade; Antioxidant effects; Cardiac ion channels; Cardiovascular protection; Carvedilol

Indexed keywords

1 [3 HYDROXYCARBAZOLYL (4) OXY] 3 [(2 METHOXYPHENOXY)ETHYLAMINO]PROPAN 2 OL; ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CARDIOVASCULAR AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLITE; HEPARIN; MEMBRANE RECEPTOR; METOPROLOL; NEUROHORMONE; NITRATE; POTASSIUM CHANNEL; REACTIVE OXYGEN METABOLITE; SB 209995; UNCLASSIFIED DRUG; VERAPAMIL;

ADRENERGIC RECEPTOR BLOCKING; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; DRUG METABOLISM; GLUCOSE METABOLISM; HEART ELECTROPHYSIOLOGY; HEART PROTECTION; HEART WORK; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; META ANALYSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; VASODILATATION;

EID: 0034909760     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00061.x     Document Type: Review

References (119)

1. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials
2. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions
3. Effects of carvedilol, a vasodilator-β-blocker in patients with congestive heart failure due to ischemic heart disease
4. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
5. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling
6. Pharmacological characteristics of the stereoisomers of carvedilol
7. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial
8. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results
9. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to ischemia and reperfusion
10. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with β-blocking agents
11. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
12. Usefulness of carvedilol in unstable angina pectoris
13. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury
14. The recognition and management of tachyarrhythmias
15. β-Blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol
16. + current in rabbit ventricular myocytes
17. 2+ current in rabbit ventricular myocytes
18. A randomized trial of β-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS)
19. Safety and efficacy of carvedilol in severe heart failure
20. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
21. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids
22. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
23. Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits
24. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
25. Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease
26. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders
27. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics and cardiac function in essential hypertension
28. Effect of selective versus nonselective beta-blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy
29. Carvedilol: A novel multiple action antihypertensive drug that provides major organ protection
30. A potent antioxidant, SB209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity
31. Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure
32. Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat
33. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol
34. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model
35. Tolerance to nitrates with enhanced radical formation suppressed by carvedilol
36. Effect of β-blockers on free radical-induced cardiac contractile dysfunction
37. Carvedilol
38. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency
39. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial
40. Carvedilol versus verapamil in chronic stable angina: A multicentre trial
41. 2-adrenoceptor subtype: Therapeutic implication
42. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs
43. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence
44. Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries
45. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1
46. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study
47. Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of β-blocking agents?
48. Antiarrhythmic drug carvedilol inhibits HERG channels
49. Nitric oxide and cardiac function
50. Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury
51. Cellular electropharmacology of amiodarone
52. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
53. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure
54. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes
55. Metabolic effects of carvedilol in hypertensive patients
56. 1-adrenoceptors by carvedilol in ferret myocardium
57. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
58. Carvedilol, a new β-adrenoceptor blocker and a free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits
59. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure
60. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension
61. Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension
62. Physiology and pharmacology of endothelins
63. Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding
64. Carvedilol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy
65. Clinical pharmacokinetics and pharmacodynamics of carvedilol
66. Results of therapy with carvedilol, a β-blocker vasodilator with antioxidant properties, in hypertensive patients
67. Evidence for enhanced vascular superoxide anion production in nitrate tolerance
68. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol
69. The interaction of the enantiomers of carvedilol with alpha-1 and beta-adrenoceptors
70. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation
71. In vitro absorption studies with carvedilol using a new model with porcine intestine called BM-RIMO (Boehringer - Mannheim ring model)
72. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
73. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury
74. Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats
75. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells
76. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R (+)- and S (-)-carvedilol
77. Contribution of beta-adrenoceptor subtypes to relaxation of colon and oesophagus and pacemaker activity of ureter in wildtype and beta(3)-adrenoceptor knockout mice
78. Quality of life in hypertensive patients treated with either carvedilol or enalapril
79. Sudden unexpected death in patients with congestive heart failure: A second frontier
80. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
81. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
82. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial
83. Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation
84. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol
85. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The GUSTO-I experience
86. The preventative effects of vasodilating β-blockers in cardiovascular disease
87. Neuro-humoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction
88. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study
89. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: Modulation of Fas/Fas ligand and caspase-3 pathway
90. Pharmacology of carvedilol: Rationale for use in hypertension, coronary heart disease, and congestive heart failure
91. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure
92. Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture
93. Kr potassium channels
94. Metabolism of carvedilol in dogs, rats, and mice
95. Effects of carvedilol on ventricular arrhythmias
96. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction
97. Carvedilol for prevention of restenosis after directional coronary atherectomy: Final results of the European Carvedilol Atherectomy Restenosis (EUROCARE) Trial
98. Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm
99. In vivo inhibition of foam cell development by probucol in Watanabe rabbits
100. Carvedilol inhibits vascular smooth muscle cell proliferation
101. Carvedilol inhibition of lipid peroxidation. A new antioxidative mechanism
102. Haemodynamic advantage of combined alpha-blockade and beta-blockade over beta-blockade alone in patients with coronary heart disease
103. Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo controlled international trial
104. Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction
105. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris
106. Effects of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
107. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
108. Preventive effects of carvedilol on nitrate tolerance - A randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol
109. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrite tolerance in patients with chronic heart failure
110. Hemodynamic differences between metoprolol and carvedilol in hypertensive patients
111. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart
112. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
113. Potentiation of natriuretic peptide action by the β-adrenergic blocker carvedilol in hypertensive rats: A new antihypertensive mechanism
114. Carvedilol, a new vasodilator and β adrenoceptor antagonist, is an antioxidant and free radical scavenger
115. Carvedilol, a new vasodilating β-adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils
116. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells
117. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol
118. Beta-blockade during and after myocardial infarction: An overview of the randomized trials
119. Carvedilol treatment of kidney graft recipients with chronic rejection